Your browser is no longer supported. Please, upgrade your browser.
Settings
UTHR United Therapeutics Corporation daily Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E5.99 EPS (ttm)20.58 Insider Own0.10% Shs Outstand43.02M Perf Week-1.88%
Market Cap5.30B Forward P/E9.00 EPS next Y13.70 Insider Trans-70.83% Shs Float42.78M Perf Month8.89%
Income1.01B PEG- EPS next Q3.38 Inst Own94.00% Short Float20.56% Perf Quarter5.22%
Sales1.57B P/S3.37 EPS this Y102.60% Inst Trans-3.41% Short Ratio15.65 Perf Half Y-0.44%
Book/sh41.02 P/B3.00 EPS next Y-13.94% ROA46.30% Target Price129.80 Perf Year-22.71%
Cash/sh21.96 P/C5.61 EPS next 5Y-2.30% ROE61.10% 52W Range97.52 - 164.04 Perf YTD-21.29%
Dividend- P/FCF12.54 EPS past 5Y46.80% ROI19.10% 52W High-24.86% Beta1.46
Dividend %- Quick Ratio4.20 Sales past 5Y19.80% Gross Margin96.60% 52W Low26.39% ATR3.34
Employees750 Current Ratio4.50 Sales Q/Q18.80% Oper. Margin75.70% RSI (14)54.03 Volatility3.14% 2.75%
OptionableYes Debt/Eq0.00 EPS Q/Q129.90% Profit Margin64.30% Rel Volume1.11 Prev Close124.84
ShortableYes LT Debt/Eq0.00 EarningsJul 28 BMO Payout0.00% Avg Volume561.87K Price123.26
Recom2.80 SMA20-1.64% SMA507.30% SMA200-1.78% Volume621,660 Change-1.27%
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Jul-31-15Reiterated Argus Buy $205 → $200
Jul-29-15Reiterated RBC Capital Mkts Sector Perform $160 → $175
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Feb-26-15Reiterated H.C. Wainwright Buy $150 → $175
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Apr-07-14Upgrade Standpoint Research Hold → Buy $118
Feb-26-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
Feb-26-14Reiterated Ladenburg Thalmann Buy $138 → $135
Aug-22-16 12:13PM  United Therapeutics Hurt By Competitive Pressure
Aug-20-16 12:05PM  This Company Could Grow Organs in the Lab -- and It's Not Organovo Holdings at Motley Fool
Aug-12-16 01:09PM  Analysts Recommendations for Celgene and Its Peers in 2016
01:09PM  How Do Celgenes Valuation Multiples Compare to Its Peers?
Aug-10-16 06:00AM  United Therapeutics Corporation To Present At The 2016 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-05-16 02:03PM  ETFs with exposure to United Therapeutics Corp. : August 5, 2016
Aug-04-16 10:14AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 4, 2016
Aug-03-16 06:44PM  These Five Stocks Show a Combination of Value and Growth
06:03PM  Worst Performance YTD: MasterCard, Lazard
03:29PM  5 Mid-Cap Stocks With Low Enterprise Multiples
01:04PM  UNITED THERAPEUTICS CORP Financials
11:04AM  Inside Amgens Analyst Recommendations for 2016
09:55AM  4 Biotech Stocks With Up to 300% Upside Potential and Upcoming Catalysts at 24/7 Wall St.
Jul-28-16 09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today +5.11%
07:07AM  Q2 2016 United Therapeutics Corp Earnings Release - Before Market Open
06:34AM  United Therapeutics tops Street 2Q forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
06:00AM  United Therapeutics Corporation Reports Second Quarter 2016 Financial Results PR Newswire
Jul-22-16 01:12PM  What Do Analysts Recommend for United Therapeutics?
01:12PM  Will Orenitram Lose Market Share to Uptravi in 2016?
01:12PM  Tyvaso Sales Expected to Fall Marginally in 2Q16
08:50AM  Why United Therapeutics (UTHR) Might Surprise This Earnings Season
08:18AM  Martine Rothblatt: Organ manufacturing could make us the next Google at bizjournals.com
Jul-21-16 06:00AM  United Therapeutics Corporation To Announce Second Quarter 2016 Financial Results Before The Market Opens On Thursday, July 28, 2016 PR Newswire
Jul-20-16 04:13PM  How Will Remodulin Sales Fare in 2Q16?
04:13PM  United Therapeutics Expects to Report Strong 2Q16 Revenue Growth
Jul-19-16 01:14PM  CEO's message to investors: My biotech is like Google before it was big at CNBC
12:26PM  3 Biotech Stocks That Could Soar Over the Next 12 Months at Motley Fool
07:43AM  Medical 'moonshot': Manufactured organs
Jul-17-16 03:03PM  3 Biotech Stocks for Conservative Investors at Motley Fool
Jul-15-16 09:05AM  Coverage Initiated on Select Drug Manufacturer Stocks
Jul-14-16 09:05AM  ALNY Should Complete Revusirans Endeavour Trial Enrollment in Late 2016
Jul-13-16 11:05AM  ALNY Reports Positive Results from Patisirans Open Label Extension Study
10:04AM  ALNY Completes Enrollment for Patisirans Phase 3 Trial in 2016
Jul-12-16 09:08PM  Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis
Jul-11-16 08:15AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : July 11, 2016
Jul-07-16 06:22PM  Merrimack Stock Up on Fast Track Status for Seribantumab
04:54PM  Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Jul-05-16 11:28AM  Merck to Acquire Brazilian Animal Health Company for $400M
Jul-02-16 12:01AM  [$$] Biotech Bargain at Barrons.com
Jul-01-16 04:52PM  10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate?
Jun-22-16 06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vo
Jun-20-16 07:09PM  Gurus Invest in Top Biotechnology Stocks
03:25PM  ETFs with exposure to United Therapeutics Corp. : June 20, 2016
Jun-15-16 07:07AM  United Therapeutics downgraded by H.C. Wainwright
Jun-14-16 09:07AM  Featured Research Report on Drug Manufacturers Stocks
Jun-13-16 02:55PM  United Therapeutics Corp. Value Analysis (NASDAQ:UTHR) : June 13, 2016
Jun-10-16 08:23AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : June 10, 2016
Jun-01-16 09:00AM  Entrepreneur and CEO Martine Rothblatt thinks well 3D print new bodies and live forever on the internet
May-24-16 08:08AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : May 24, 2016
May-16-16 06:54PM  ETFs with exposure to United Therapeutics Corp. : May 16, 2016
09:48AM  Aging Is So Yesterday at Forbes
May-10-16 11:37AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q1, 2016 By the Numbers
May-04-16 02:05PM  XBIs Mid Caps: Ionis Gives Update on Nusinersen Phase 2 Study Market Realist
08:04AM  3 Dirt-Cheap Biotech Stocks To Buy at Motley Fool
Apr-29-16 11:54AM  United (UTHR) Stock Declines Despite Q1 Earnings Beat
Apr-28-16 04:48PM  The 52-Week Low Club for Thursday at 24/7 Wall St. -10.91%
12:02PM  What's Behind United Therapeutics' Slumping Shares Today at Motley Fool
11:33AM  Edited Transcript of UTHR earnings conference call or presentation 28-Apr-16 1:00pm GMT Thomson Reuters StreetEvents
11:05AM  Roger Jeffs out in executive shakeup at drugmaker United Therapeutics at American City Business Journals
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today CCBN
07:07AM  Q1 2016 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:24AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:17AM  United Therapeutics beats 1Q profit forecasts AP
06:12AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:05AM  United Therapeutics Corporation Announces Executive Leadership Changes PR Newswire
06:00AM  United Therapeutics Corporation Reports First Quarter 2016 Financial Results PR Newswire
Apr-27-16 06:00AM  United Therapeutics Corporation To Present At Deutsche Bank 41st Annual Health Care Conference PR Newswire
Apr-25-16 08:30AM  SteadyMed Announces Public Availability of PTAB Decision to Institute Inter Partes Review Proceedings GlobeNewswire
Apr-14-16 07:30AM  SteadyMed to Host an Analyst and Investor Reception GlobeNewswire
Apr-11-16 02:20PM  UAB lands $19.5 million grant from biotech giant to start kidney transplant research at bizjournals.com
07:00AM  SteadyMed Announces Initiation of Inter Partes Review Proceedings by U.S. Patent and Trademark Office Against a United Therapeutics Patent GlobeNewswire
Apr-07-16 07:34AM  Financial engineering 'sucking money out of R&D': UTHR CE...
Apr-01-16 02:35PM  United Therapeutics, Supernus sue PTO over patent at bizjournals.com
Mar-30-16 04:03PM  United Therapeutics Has Room to Fall Farther
Mar-28-16 10:50AM  United Therapeutics Tanks, Remodulin Pump Faces Setback
Mar-24-16 03:01PM  Maryland's next big manufacturing industry: Human organs, says Martine Rothblatt at bizjournals.com -10.47%
11:48AM  United Therapeutics Down As FDA Rejects Medtronics Remodulin Pump
06:13AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
Mar-23-16 08:21AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : March 23, 2016
Mar-10-16 01:19PM  United Therapeutics Corp. Value Analysis (NASDAQ:UTHR) : March 10, 2016
Mar-09-16 08:12AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : March 9, 2016
08:07AM  How Are IBBs Mid-Caps Faring as of March 7?
Mar-08-16 12:59PM  3 Plays for the Biotech Bear Market (GILD, UTHR) at Investopedia -5.36%
06:00AM  United Therapeutics Corporation To Present At Barclays Global Healthcare Conference PR Newswire
Mar-07-16 06:00AM  The Obsession With Curing Aging Is Now Big Business at Fortune
Mar-02-16 11:15AM  Palo Altos Top Picks for This Year Following Impressive 2015 Returns at Insider Monkey
Mar-01-16 06:40AM  United Therapeutics sees stepped-up competition and says it's 'a good thing' at bizjournals.com
Feb-26-16 04:01PM  United Therapeutics Tops on 4Q Revenues, Earnings Up Y/Y
Feb-25-16 12:32PM  Edited Transcript of UTHR earnings conference call or presentation 25-Feb-16 2:00pm GMT
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today
07:07AM  Q4 2015 United Therapeutics Corp Earnings Release - Before Market Open
06:39AM  United Therapeutics beats Street 4Q forecasts
06:18AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:12AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report
06:00AM  United Therapeutics Corporation Reports 2015 Fourth Quarter And Annual Financial Results PR Newswire
Feb-22-16 08:30AM  Healthcare Booming for Synergy, DepoMed, Novo Nordisk and United Therapeutics Accesswire
Feb-19-16 06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Other Events
Feb-18-16 08:30PM  United Therapeutics Corporation To Announce Fourth Quarter And Annual 2015 Financial Results Before Market Open On Thursday, February 25, 2016 PR Newswire
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's principal therapeutic products and product candidates include Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH); Tyvaso, an inhaled prostacyclin therapy for PAH; Adcirca, a once-daily oral therapy for PAH; Orenitram, a prostacyclin analog for PAH; Unituxin, an antibody that binds to cancerous tumors and destroys the cancer cells; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & CEOAug 18Option Exercise30.751,24938,4071,389Aug 19 04:16 PM
ROTHBLATT MARTINE AChairman & CEOAug 18Option Exercise30.7592828,536635,786Aug 19 04:16 PM
MAHON PAUL AEVP & General CounselAug 18Option Exercise50.096,000300,54041,221Aug 22 09:26 AM
ROTHBLATT MARTINE AChairman & CEOAug 18Sale125.881,249157,223140Aug 19 04:16 PM
ROTHBLATT MARTINE AChairman & CEOAug 11Option Exercise30.751,25338,5301,393Aug 15 09:50 AM
ROTHBLATT MARTINE AChairman & CEOAug 11Option Exercise30.7592328,382634,858Aug 15 09:50 AM
ROTHBLATT MARTINE AChairman & CEOAug 11Sale124.091,253155,487140Aug 15 09:50 AM
ROTHBLATT MARTINE AChairman & CEOAug 04Option Exercise30.7592828,536633,935Aug 05 04:17 PM
ROTHBLATT MARTINE AChairman & CEOAug 04Option Exercise30.751,24938,4071,389Aug 05 04:17 PM
PATUSKY CHRISTOPHERDirectorAug 04Option Exercise48.113,000144,3303,000Aug 05 04:14 PM
DWEK RAYMONDDirectorAug 04Option Exercise51.773,000155,3103,000Aug 05 04:13 PM
CAUSEY CHRISTOPHERDirectorAug 04Option Exercise51.771,25064,7132,355Aug 05 04:12 PM
MAHON PAUL AEVP & General CounselAug 04Option Exercise50.096,000300,54041,221Aug 05 04:18 PM
ROTHBLATT MARTINE AChairman & CEOAug 04Sale125.781,249157,101140Aug 05 04:17 PM
ROTHBLATT MARTINE AChairman & CEOJul 28Option Exercise30.751,27139,0831,411Aug 01 06:25 AM
ROTHBLATT MARTINE AChairman & CEOJul 28Option Exercise30.7590527,829633,007Aug 01 06:25 AM
ROTHBLATT MARTINE AChairman & CEOJul 28Sale117.051,271148,774140Aug 01 06:25 AM
ROTHBLATT MARTINE AChairman & CEOJul 21Option Exercise30.751,28439,4831,424Jul 22 04:11 PM
ROTHBLATT MARTINE AChairman & CEOJul 21Option Exercise30.7589227,429632,102Jul 22 04:11 PM
CAUSEY CHRISTOPHERDirectorJul 21Option Exercise51.7775038,8281,855Jul 22 04:10 PM
MAHON PAUL AEVP & General CounselJul 21Option Exercise50.096,000300,54041,221Jul 22 04:12 PM
ROTHBLATT MARTINE AChairman & CEOJul 21Sale112.771,284144,791140Jul 22 04:11 PM
ROTHBLATT MARTINE AChairman & CEOJul 14Option Exercise30.751,29239,7291,432Jul 15 04:04 PM
ROTHBLATT MARTINE AChairman & CEOJul 14Option Exercise30.7588427,183631,210Jul 15 04:04 PM
ROTHBLATT MARTINE AChairman & CEOJul 14Sale110.051,292142,180140Jul 15 04:04 PM
DWEK RAYMONDDirectorJul 08Option Exercise51.173,000153,5103,000Jul 12 11:01 AM
MAHON PAUL AEVP & General CounselJul 07Option Exercise50.096,000300,54041,221Jul 08 04:07 PM
ROTHBLATT MARTINE AChairman & CEOJul 07Option Exercise30.751,29339,7601,433Jul 08 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJul 07Option Exercise30.7588427,183630,329Jul 08 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJul 07Sale109.871,293142,064140Jul 08 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJun 30Option Exercise30.7586826,691629,445Jul 01 04:02 PM
ROTHBLATT MARTINE AChairman & CEOJun 30Option Exercise30.751,30840,2211,548Jul 01 04:02 PM
ROTHBLATT MARTINE AChairman & CEOJun 30Sale105.101,308137,470240Jul 01 04:02 PM
ROTHBLATT MARTINE AChairman & CEOJun 23Option Exercise30.7586426,568628,577Jun 27 07:35 AM
ROTHBLATT MARTINE AChairman & CEOJun 23Option Exercise30.751,31240,3441,552Jun 27 07:35 AM
ROTHBLATT MARTINE AChairman & CEOJun 23Sale104.071,312136,542240Jun 27 07:35 AM
ROTHBLATT MARTINE AChairman & Co-CEOJun 16Option Exercise30.751,30840,2211,548Jun 16 05:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 16Option Exercise30.7586826,691627,713Jun 16 05:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 16Sale105.181,308137,571240Jun 16 05:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 09Option Exercise30.7589927,644626,845Jun 13 07:27 AM
ROTHBLATT MARTINE AChairman & Co-CEOJun 09Option Exercise30.751,27739,2681,517Jun 13 07:27 AM
ROTHBLATT MARTINE AChairman & Co-CEOJun 09Sale114.991,277146,836240Jun 13 07:27 AM
Thompson Tommy GDirectorJun 08Option Exercise52.652,000105,3002,000Jun 09 05:09 PM
Thompson Tommy GDirectorJun 08Sale115.622,000231,2470Jun 09 05:09 PM
DWEK RAYMONDDirectorJun 02Option Exercise41.143,000123,4203,000Jun 03 08:08 AM
ROTHBLATT MARTINE AChairman & Co-CEOJun 02Option Exercise30.751,26138,7761,501Jun 03 04:02 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 02Option Exercise30.7591528,136625,946Jun 03 04:02 PM
MAHON PAUL AEVP & General CounselJun 02Option Exercise50.096,000300,54041,221Jun 03 04:04 PM
CAUSEY CHRISTOPHERDirectorJun 02Option Exercise51.7775038,8281,855Jun 03 04:05 PM
DWEK RAYMONDDirectorJun 02Sale118.823,000356,4480Jun 03 08:08 AM
ROTHBLATT MARTINE AChairman & Co-CEOJun 02Sale120.791,261152,315240Jun 03 04:02 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 26Option Exercise30.755,547170,5705,787May 31 08:19 AM
ROTHBLATT MARTINE AChairman & Co-CEOMay 26Sale117.575,547652,146240May 31 08:19 AM
CAUSEY CHRISTOPHERDirectorMay 20Option Exercise51.7775038,8281,855May 25 08:31 AM
MAHON PAUL AEVP & General CounselMay 19Option Exercise48.856,000293,09441,221May 23 04:21 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 19Option Exercise30.755,546170,5405,786May 20 04:03 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 19Sale110.755,546614,205240May 20 04:03 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMay 13Option Exercise70.09111,2507,798,015112,792May 16 04:13 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 12Option Exercise30.755,547170,5705,787May 13 04:04 PM
DWEK RAYMONDDirectorMay 12Option Exercise41.143,000123,4203,000May 13 04:07 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 12Sale109.025,547604,746240May 13 04:04 PM
DWEK RAYMONDDirectorMay 12Sale110.003,000330,0000May 13 04:07 PM
PATUSKY CHRISTOPHERDirectorMay 05Option Exercise48.113,000144,3303,000May 06 04:04 PM
MAHON PAUL AEVP & General CounselMay 05Option Exercise47.506,000285,00041,221May 06 04:05 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 05Option Exercise30.755,546170,5405,786May 06 04:06 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 05Sale107.795,546597,781240May 06 04:06 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 28Option Exercise30.755,547170,5705,787Apr 29 04:06 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 28Sale106.815,547592,499240Apr 29 04:06 PM
MAHON PAUL AEVP & General CounselApr 21Option Exercise47.506,000285,00041,221Apr 25 04:13 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 21Option Exercise30.755,546170,5405,786Apr 25 04:14 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 21Sale115.745,546641,922240Apr 25 04:14 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 14Option Exercise30.755,547170,5705,787Apr 18 04:24 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 14Sale114.325,547634,116240Apr 18 04:24 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 07Option Exercise30.755,546170,5405,786Apr 08 05:14 PM
MAHON PAUL AEVP & General CounselApr 07Option Exercise47.506,000285,00041,221Apr 08 05:14 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 07Sale113.315,546628,420240Apr 08 05:14 PM
CAUSEY CHRISTOPHERDirectorApr 01Option Exercise51.7775038,8281,708Apr 04 04:11 PM
DWEK RAYMONDDirectorApr 01Option Exercise41.143,000123,4203,000Apr 04 04:12 PM
DWEK RAYMONDDirectorApr 01Sale110.813,000332,4280Apr 04 04:12 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 24Option Exercise30.755,546170,5405,786Mar 28 04:13 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 24Sale110.805,546614,500240Mar 28 04:13 PM
MAHON PAUL AEVP & General CounselMar 17Option Exercise47.506,000285,00041,221Mar 18 04:09 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 17Option Exercise30.755,547170,5705,787Mar 18 04:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 17Sale118.225,547655,769240Mar 18 04:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 10Option Exercise30.755,546170,5405,786Mar 11 04:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 10Sale123.415,546684,446240Mar 11 04:00 PM
CAUSEY CHRISTOPHERDirectorMar 03Option Exercise51.7775038,8281,708Mar 04 04:58 PM
DWEK RAYMONDDirectorMar 03Option Exercise41.143,000123,4203,000Mar 04 05:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 03Option Exercise30.755,547170,5705,787Mar 04 04:59 PM
MAHON PAUL AEVP & General CounselMar 03Option Exercise50.096,000300,54041,054Mar 04 04:57 PM
PATUSKY CHRISTOPHERDirectorMar 03Option Exercise48.113,000144,3303,000Mar 04 04:59 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 03Sale126.785,547703,276240Mar 04 04:59 PM
Thompson Tommy GDirectorMar 01Option Exercise48.113,000144,3303,000Mar 03 10:06 AM
Thompson Tommy GDirectorMar 01Sale126.543,000379,6200Mar 03 10:06 AM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 25Option Exercise30.755,546170,5405,786Feb 26 05:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 25Sale122.455,546679,104240Feb 26 05:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 18Option Exercise30.755,547170,5705,787Feb 22 05:34 PM
MAHON PAUL AEVP & General CounselFeb 18Option Exercise50.096,000300,54041,054Feb 22 05:33 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 18Sale128.265,547711,435240Feb 22 05:34 PM
JEFFS ROGERPresident & Co-CEOFeb 12Option Exercise65.809,000592,2009,559Feb 17 04:10 PM